OSAM
KPTI icon

O'Shaughnessy Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

O'Shaughnessy Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,463
Closed -$19K – 2160
2024
Q2 		$19K Buy
+1,463
New +$24.2K ﹤0.01% 1804
2021
Q4 		– Sell
-50
Closed -$4K – 1890
2021
Q3 		$4K Hold
50
– – ﹤0.01% 2379
2021
Q2 		$8K Hold
50
– – ﹤0.01% 2042
2021
Q1 		$8K Hold
50
– – ﹤0.01% 1824
2020
Q4 		$12K Hold
50
– – ﹤0.01% 1518
2020
Q3 		$11K Hold
50
– – ﹤0.01% 1338
2020
Q2 		$14K Buy
+50
New +$14.8K ﹤0.01% 1202
2020
Q1 		– Sell
-61
Closed -$18K – 1559
2019
Q4 		$18K Buy
+61
New +$13.2K ﹤0.01% 1167

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

O'Shaughnessy Asset Management's KPTI Position: Q3 2024 in Review

O'Shaughnessy Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 1,463 shares — an estimated $19K sold.

O'Shaughnessy Asset Management first reported a position in KPTI in Q4 2019 and held it in 8 quarters. The position peaked at $19K in Q2 2024. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • O'Shaughnessy Asset Management reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • O'Shaughnessy Asset Management sold 1,463 Karyopharm Therapeutics shares in Q3 2024, an estimated $19K.
  • O'Shaughnessy Asset Management first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 8 quarters.
  • O'Shaughnessy Asset Management's Karyopharm Therapeutics position peaked at $19K in Q2 2024.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on O'Shaughnessy Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.